SENSCIS
2019
Nintedanib in Systemic Sclerosis-Associated ILD
In 576 patients with SSc-associated ILD, nintedanib slowed annual FVC decline compared with placebo.
Result
Primary endpoint: Annual rate of FVC decline
-52.4 vs -93.3 mL/year (44% reduction; p=0.04).
- Subtopic
- SSc-ILD
- Design
- Multicentre RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Distler O, et al. N Engl J Med. 2019;380(26):2518-2528.doi 10.1056/NEJMoa1903076
Discussion & critique
Third FDA indication for nintedanib.